| Date | Panel | Item | Activity | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| COVID-19 research v0.176 | CYP2B6 | Sarah Leigh reviewed gene: CYP2B6: Rating: RED; Mode of pathogenicity: ; Publications: 15622315, 20860463, 15194512, 23418033; Phenotypes: {Efavirenz central nervous system toxicity, susceptibility to} 614546, Efavirenz, poor metabolism of 614546; Mode of inheritance: BIALLELIC, autosomal or pseudoautosomal | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| COVID-19 research v0.121 | CYP2B6 |
Sarah Leigh gene: CYP2B6 was added gene: CYP2B6 was added to Viral susceptibility. Sources: OMIM Mode of inheritance for gene: CYP2B6 was set to |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||